Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

NCT02226120 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1980

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Heart Failure With Reduced Ejection Fraction

Interventions

DRUG: LCZ696

Sponsor

Novartis Pharmaceuticals